DUSP2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Mk-0893 (SCHEMBL675777)	1.00	1/20
Mk-0893 (SCHEMBL2355321)	1.00	1/20
Mk-0893 (SCHEMBL29363684)	1.00	1/20
SCHEMBL13644751	0.88	1/20
SCHEMBL2667510	0.84	1/20
SCHEMBL2667874	0.84	1/20
SCHEMBL2667512	0.83	1/20
SCHEMBL3251729	0.83	1/20
SCHEMBL825813	0.83	1/20
SCHEMBL827984	0.83	1/20
SCHEMBL1966239	0.83	1/20
SCHEMBL2644669	0.82	1/20
SCHEMBL826673	0.81	1/20
SCHEMBL16830702	0.80	1/20
SCHEMBL2667967	0.78	1/20
SCHEMBL9071306	0.78	1/20
SCHEMBL2644824	0.76	1/20
SCHEMBL28578321	0.75	1/20
SCHEMBL4127496	0.74	1/20
SCHEMBL2645995	0.73	1/20

Clinical trials — most relevant to DUSP2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Efficacy and Safety of 0.25% Timolol Gel in Healing Surgical Open Wounds	PHASE2/PHASE3	COMPLETED
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer	PHASE2	COMPLETED
Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study)	PHASE1/PHASE2	WITHDRAWN
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer	PHASE1/PHASE2	COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer	PHASE2	COMPLETED
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma	PHASE1/PHASE2	SUSPENDED
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLC	PHASE2	COMPLETED
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma	PHASE1/PHASE2	COMPLETED
Imatinib in Dermatofibrosarcoma Protuberans (DFSP)	PHASE1/PHASE2	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Bioequivalence Study of Tacrolimus in Healthy Volunteers	PHASE1	COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL)	PHASE1	COMPLETED
Palliative Thoracic Radiotherapy Plus BKM120	PHASE1	COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors	PHASE1	NOT_YET_RECRUITING
Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease	nan	UNKNOWN
Biomarkers in Samples From Patients With Chronic Lymphocytic Leukemia Treated on Clinical Trial ECOG-2997	nan	COMPLETED
Quantification of GADD34 Expression in RA	nan	COMPLETED
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED
Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia	nan	UNKNOWN
Uncovering Genes Behind Cartilage Tumors and Vascular Anomalies Using Genomic Sequencing	nan	RECRUITING
Vulvodynia: Identification of Potential Relevant Biomarkers	nan	COMPLETED
Role of NFKBIA and PTPN22 Genes Polymorphism in Acute Rejection Susceptibility After Living Donor Liver Transplantation in Egyptian Patients.	nan	COMPLETED
Genetic Identification (ID) of Segmental Dysplastic Nevi	nan	WITHDRAWN
IVF Outcome in Polycystic Ovary Syndrome Patients	nan	UNKNOWN
NGS in Gallbladder Cancer and Response to Treatment	nan	RECRUITING
Identification of Novel Targetable Kinases in SR-a GvHD	nan	COMPLETED
What is the Impact of TKI on Thyroid Function in CML Patients?	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a DUSP2 binder may also engage these)

Protein	Name	Similarity
Q05922	—	1.000	Q05922 →
O54838	—	0.981	O54838 →
Q9PW71	—	0.980	Q9PW71 →
Q99956	—	0.977	Q99956 →
DUSP5	Dual specificity protein phosphatase 5	0.974	landscape →
P28563	—	0.971	P28563 →
Q64623	—	0.969	Q64623 →
Q96EY9	—	0.967	Q96EY9 →
Q6B8I1	—	0.965	Q6B8I1 →
DUSP4	Dual specificity protein phosphatase 4	0.965	landscape →
DUSP1	Dual specificity protein phosphatase 1	0.965	landscape →
Q561R2	—	0.964	Q561R2 →
Q62767	—	0.964	Q62767 →
Q6PAT0	—	0.962	Q6PAT0 →
Q17QJ3	—	0.961	Q17QJ3 →
Q16829	—	0.961	Q16829 →
Q6B8I0	—	0.961	Q6B8I0 →
Q5FVI9	—	0.961	Q5FVI9 →
Q63340	—	0.959	Q63340 →
DUSP26	Dual specificity protein phosphatase 26	0.958	landscape →
A5GFZ6	—	0.958	A5GFZ6 →
PKN3	Serine/threonine-protein kinase N3	0.957	landscape →
A1A4L8	—	0.957	A1A4L8 →
Q8K2J0	—	0.957	Q8K2J0 →
Q91Z46	—	0.957	Q91Z46 →
Q8K045	—	0.957	Q8K045 →
Q8BFV3	—	0.957	Q8BFV3 →
Q8BTR5	—	0.957	Q8BTR5 →
Q5R6H6	—	0.956	Q5R6H6 →
A2BDX3	—	0.955	A2BDX3 →